Clinical trials: Obesity & Overweight
Obesity
Feasibility Trial of ValenTx Endo Bypass System
The purpose of the study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese patients.
- Trial name
- NCT01207804
- Testing
- ValenTx Endo Bypass System
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- ValenTx, Inc.
Type 2 Diabetes Mellitus, Overweight and Obesity
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of the study drug ZGN-1061 in participants with type 2 diabetes.
- Trial name
- NCT03254368
- Testing
- ZGN-1061
- Where
- 23 sites in Australia, New Zealand
- Volunteers
- 188 people
- Sponsor
- Zafgen, Inc.
Obesity
Clinical Feasibility Study of the BariTon™ System in Obese or Overweight Patients.
Safety and efficacy evaluation of the BariTon™, BariaTek Medical gastric restriction and biliodigestive diversion device.
- Trial name
- NCT06360679
- Testing
- Endoscopic gastric restriction and biliodigestive diversion
- Where
- 2 sites in Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- BariaTek Medical
Overweight, Obesity
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
The purpose of this study is to determine how VI-0521 affect speed and reaction time on specific tasks that require eye and hand coordination, compared to placebo.
- Trial name
- NCT00806260
- Testing
- VI-0521, Alcohol
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Obesity, Morbid Obesity
Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102
The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.
- Trial name
- NCT01539850
- Testing
- OMS102
- Where
- 3 sites in Germany
- Volunteers
- 34 people
- Sponsor
- IntraPace, Inc
Overweight , Obesity
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants…
- Trial name
- NCT07791524
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Morbid Obesity, Metabolic Disease
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. Patients with this syndrome are at increased risk for cardiovascular disease, and at increased risk of mortality…
- Trial name
- NCT00283374
- Testing
- Laparoscopic Roux-en-Y Gastric Bypass
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Obesity, Type 2 Diabetes
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a…
- Trial name
- NCT07702890
- Testing
- GUB-UCN2
- Where
- Germany
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Gubra A/S
Obesity or Overweight
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for…
- Trial name
- ASCEND (NCT06862791)
- Testing
- AZD9550, AZD6234
- Where
- 53 sites in United States, Australia and 3 more
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Overweight and/or Obesity, Healthy Participants
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a…
- Trial name
- NCT07828197
- Testing
- HDM1005
- Where
- China
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity
The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study.
- Trial name
- NCT07508020
- Testing
- NNC0487-0111
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants…
- Trial name
- SLIM-1 (NCT07430059)
- Testing
- Semaglutide Implant (NPM-139), Semaglutide (Wegovy) weekly injection
- Volunteers
- 20 people
- Sponsor
- Vivani Medical, Inc
Obesity or Overweight
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with…
- Trial name
- ZYNERGY (NCT07589686)
- Testing
- Petrelintide, Enicepatide
- Volunteers
- 486 people
- Sponsor
- Hoffmann-La Roche
Obesity
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
- Trial name
- NCT00112021
- Testing
- pramlintide acetate
- Where
- 21 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Body Weight
Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss
The trial was designed to provide empirical evidence with which to compare the efficacy and safety of the invisa-RED Technology Elite Low-level Laser Therapy (LLLT) device with a sham device as a placebo, when both are used in…
- Conditions
- Obesity, Body Weight, Fat Burn, Cellulite
- Trial name
- NCT03811093
- Testing
- Care as Usual Group
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- IR Technology, LLC
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
This is a randomized, placebo-controlled, double-blind, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of ASC36 Tablets for Oral Use in Adult…
- Trial name
- NCT07893106
- Testing
- ASC36 tablets, for oral use
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight or Obesity
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.
- Trial name
- NCT06621316
- Testing
- HRS-7535 Tablet
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.
- Trial name
- NCT02527200
- Testing
- liraglutide
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.